• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Four healthcare consequences of King v. Burwell


Stuart M. Gerson, member of Epstein Becker Green's Litigation and Health Care & Life Sciences practices, discusses four possible consequences of the King v. Burwell ruling.

The much-anticipated Supreme Court 6-3 ruling in King v. Burwell, upholding the key provision of the Affordable Care Act (ACA) regarding tax credit subsidies payable to economically eligible persons, while wildly anticipated, is unsurprising. Neither, is the majority opinion, for that matter, or the fact that it was written by Chief Justice John Roberts.

This marks the second time that the Chief Justice has authored a controversial decision rescuing the ACA from judicial uprooting. In National Federation of Independent Business v. Sebelius, the Chief Justice opined that - despite the way it was originally described by the Administration and its supporters in the Congress and the statute itself as a “penalty” (questionable under the Constitution’s Commerce Clause) to which certain non-purchasers of health insurance would be subjected under the individual mandate - the penalty actually should be treated as a tax (consistent with the Constitution’s taxation provision). This time, I believe, the Chief Justice was on stronger legal and logical ground as to the ACA’s tax credit provision.

Related: Oral arguments in King v. Burwell

On its face, the provision at issue in King limited the relevant subsidies to persons who could participate in “an Exchange established by the State under [42 U. S. C. §18031].” To Justice Scalia and the other two dissenters, this apparently plain language should have ended the inquiry.  Thus, Scalia chastises the majority for having created “SCOTUScare” and having engaged in “somersaults of statutory interpretation.”

However, the Chief Justice has a compelling position to the contrary. In gleaning congressional intent, he noted not only the centrality of the tax credits to the overall scheme of the ACA, but looking to other parts of the statute which described the availability of the credits to eligible persons generally without reference to exchanges, concluded that there was no real difference between exchanges established by the states and those established by the federal government.

Ultimately, the majority held that “Congress passed the Affordable Care Act to improve health insurance markets, not to destroy them. If at all possible, we must interpret the Act in a way that is consistent with the former, and avoids the latter. [The ACA] can fairly be read consistent with what we see as Congress’s plan, and that is the reading we adopt.”


NEXT: The consequences of the court's decision


There are several healthcare consequences that likely will follow from the Court’s decision.  The first is the political momentum from which the Obama Administration continues to benefit. The ACA is the centerpiece of whatever legacy President Obama will have and he will leave office with the program essentially intact. Administration bureaucrats can now proceed with their regulatory activities free from the specter of the ACA’s collapse.

Related:Study: ACA will reduce costs for many

Second, and perhaps most importantly, health insurers now gain the certainty that is required for proper rate setting. Had the subsidies at issue in King not been available to economically eligible persons, would insurance risk pools have been thrown into disarray? These persons generally are young and relatively healthy. If they could not get the credits, which would have put them in an income situation that required them to purchase health insurance and hence could opt out of the system, insurers would have been faced with statistically unhealthier populations and rates would have had to increase substantially, threatening the entire balance that the ACA was intended to provide. Relatedly, health insurance subscribers generally will be able to make more affordable and predictable choices in upcoming open seasons.

Related: The countdown to King v. Burwell

Third, eligible employers, particularly smaller businesses, likely will be spurred more quickly to comply with their ACA mandate and will encourage their employees to purchase health insurance (if they are not providing it).

Fourth, a bit more speculatively, will be the effect on the states and their exchanges. The literal language of section 18031 made it more advantageous to citizens of states that had their own exchanges.  However, now that any useful distinction between state and federal exchanges has been removed by the Supreme Court, there is little incentive for new state exchanges.

One thus foresees an increasing federal presence at the grass roots of health insurance as the result of a case that marks the triumph of “contextualism” over strict “textualism.”

Stuart M. Gerson is a member of Epstein Becker Green’s Litigation and Health Care & Life Sciences practices.

Related Content
© 2024 MJH Life Sciences

All rights reserved.